Skip to main content

Kristalose® - NC Standard

Commercial Policy
Version Date: December 2023

Restricted Product(s)

Restriction applies to brand and generic products

  • Kristalose® powder packets 

FDA Approved Use

  • For the treatment of constipation.

Criteria for Approval of Restricted Product(s)

  1. The patient has a diagnosis of constipation; AND 
  2. The patient has tried and failed Lactulose solution (i.e. Constulose, Enulose); OR 
    1. The provider gives a written statement demonstrating that the patient is likely to undergo harm by utilizing a solution as opposed to the requested powder packets; AND 
  3. For formularies that exclude (non-formulary) the requested medication, Non-formulary Exception Criteria applies.

Duration of Approval: 365 days (1 year)

References

All information referenced is from FDA package insert unless otherwise noted below.

Policy Implementation/Update Information

Criteria and treatment protocols are reviewed annually by the Blue Cross NC P&T Committee, regardless of change. This policy is reviewed in Q2 annually.

December 2023: Criteria update: Formatting updates only

May 2021: Criteria update: Annual criteria review. Format updates only.

July 2019: Original utilization management criteria issued.

Disclosures:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.